- Press Release -

Rockville, Md. The global antibodies market is set to surpass US$ 3 Bn by 2022 on moderate growth, according to Fact.MR. Rising incidence of chronic conditions such as diabetes, cancer and autoimmune disease is pushing drug makers to refine antibody-based products, while the growing popularity of protein therapeutics adds to demand.

Primary antibodies lead the product mix, academic and research institutes are the largest end user, and basic research is the top application. North America dominates by revenue.

Products, End Users and Applications

Primary antibodies hold the largest revenue share, with more than US$ 1 Bn expected to sell by 2022. Among end users, academic and research institutes lead at over a third of revenue and pass US$ 1.286 Bn by 2022. By application, basic research holds the top position and is set to exceed US$ 1.741 Bn by 2022 at over a 3% CAGR, with antibodies used widely in diagnostics and new drug development.

North America holds the predominant share and expands at a steady CAGR through the forecast period, supported by advanced healthcare infrastructure and a strong base of market participants.

Research and Disease Drive Demand

The market runs on research and clinical need. As chronic and epidemic disease burdens grow and protein therapeutics gain favour, antibody demand holds firm, though rising availability of alternative therapeutics, affordability concerns and the risk of side effects temper the outlook.

Suppliers and Their Playbook

The field brings together life-science reagent and biotech companies.

• Thermo Fisher Scientific, Inc., Sigma Aldrich Corp, Bio-Rad Laboratories, Inc., Abcam Plc, Crown Bioscience, Inc., A.M.S. Biotechnology (Europe) Limited, Cell Signaling Technology, and Genscript Biotech Corporation are among the key players in the report.

Reading the Market for Decisions

For suppliers, growth favours primary antibodies and research-focused portfolios. Investors get a market with steady, research-led demand. Procurement and lab teams can plan around primary antibodies carrying volume, academic and research institutes leading demand, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global antibodies market for the 2017 to 2022 forecast period, with segmentation by product type, end user, application and region. It sizes each segment, maps the competitive field, and weighs the demand forces shaping the market. Further detail is available in the antibodies market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.